The benefits and risks of HUMIRA should be carefully considered before starting therapy.
Prior to treatment, patients involved in the studies reported moderate to severe migraine pain, with symptoms such as nausea and sensitivity to light and sound. Results showed that a high percentage of patients were able to gain relief from their migraine pain, some in as little as two hours after treatment. The most common side effect reported was nausea and dry mouth.
AveXis president Lennon acknowledges the numbers might seem shocking. But he argues the drug is easily worth it. The only existing treatment for spinal muscular atrophy, a drug called Spinraza, costs hundreds of thousands of dollars a year. Zolgensma hopefully will be a one-time, life-saving treatment.
The therapy, Palforzia, isn’t a cure and comes with significant risks of triggering the very reactions it is supposed to quell. But for families and children who have re-engineered their routines to minimize potential exposures — changing how and whether they travel, eat out, socialize and feel safe in their daily lives — it could offer an important layer of protection and relief.
Sophia Genetics has named Philippe Menu as chief medical officer. Menu joined the Swiss bioinformatics company from McKinsey, where he was co-leader of the McKinsey Cancer Center. A physician with a PhD in molecular biology, Menu primarily advised pharmaceutical and biotech companies in the development of new therapies and diagnostics in oncology and rare diseases. At Sophia, he will lead the firm's medical strategy.
People seeking information answer questions about their age, gender, medical history, and what they would tell a human doctor about their health. MedWhat takes these variables and automatically generates an answer, using information culled from legitimate medical databases like NIH and the CDC. It does not give diagnoses or treatment recommendations, but helps people understand whether they need medical attention in the first place.
Through its Genomic Medicine Initiative (GMI), UCSF has integrated data from a comprehensive cancer genetic testing program into the electronic medical records of patients at the UCSF Medical Center. Not only does it allow for continuity of care with all testing and treatment results tied to the same electronic record, but it also allows physicians and researchers to identify larger patterns in the data that can lead to the development of better treatments – which is known as precision medicine.